HMG Biologics

HMG BiologicsHMG BiologicsHMG Biologics

HMG Biologics

HMG BiologicsHMG BiologicsHMG Biologics
  • Home
  • MEDICAL AND SOCIAL NEED
  • FUTURE STEPS
  • More
    • Home
    • MEDICAL AND SOCIAL NEED
    • FUTURE STEPS
  • Home
  • MEDICAL AND SOCIAL NEED
  • FUTURE STEPS

THE MEDICAL AND SOCIAL NEED

THE NEED

  About1%-2% of the adult population will suffer from a leg ulcer, with higher incidence in females. These figures may be as high as 3%-5% in those aged 65 or more (approx. 80 million individuals are over 65 in EU 28, according to Eurostat).

In the US, chronic leg and foot ulcers affect approx. 7 million people a year (and are  becoming more prevalent as the US population age increases.

KC Plus and FB Plus are likely to be suitable for use in up to 90% of patients with chronic leg and foot ulcers.

THE CHALLENGE

 Chronic lower extremity ulcers are a big challenge to health care systems worldwide for their high frequency and for the still largely unmetcure. The total incidence of chronic wounds is estimated between 3% and 5% of total health care cost in Europe, which translates into a cost between €19 to €38 billion (Posnett, J et. al. Wound Care (April 2009), The Resource impact of Wounds on Healthcare Providers in Europe, vol. 18 (4))  

Copyright © 2025 HMG Biologics - All Rights Reserved.

Powered by